Evidence map›Paper›PMID 38702193›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2024

Comparison of the CYP3A Selective Inhibitors CYP3cide, Clobetasol, and Azamulin for Their Potential to Distinguish CYP3A7 Activity in the Presence of CYP3A4/5.

Hannah M Work, Sylvie E Kandel, Jed N Lampe

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hannah M WorkDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado (H.M.W., S.E.K., J.N.L.).
Sylvie E KandelDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado (H.M.W., S.E.K., J.N.L.).
Jed N LampeDepartment of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado (H.M.W., S.E.K., J.N.L.) jed.lampe@cuanschutz.edu.ORCID 0000-0003-0794-2263

Funding

Understanding the underlying toxicological mechanisms of drug-hormone interactions to improve the safety profile of antiviral medications in pregnant people, developing fetuses, and neonatesR01AI183687 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Jed Noah Lampe · 2024 to 2026
$1.7M
NIAID NIH HHS R01 AI183687
6 · The paper itself

Abstract

The CYP3A7 enzyme accounts for ∼50% of the total cytochrome P450 (P450) content in fetal and neonatal livers and is the predominant P450 involved in neonatal xenobiotic metabolism. Additionally, it is a key player in healthy birth outcomes through the oxidation of dehydroepiandrosterone (DHEA) and DHEA-sulfate. The amount of the other hepatic CYP3A isoforms, CYP3A4 and CYP3A5, expressed in neonates is low but highly variable, and therefore the activity of individual CYP3A isoforms is difficult to differentiate due to their functional similarities. Consequently, a better understanding of the contribution of CYP3A7 to drug metabolism is essential to identify the risk that drugs may pose to neonates and developing infants. To distinguish CYP3A7 activity from CYP3A4/5, we sought to further characterize the selectivity of the specific CYP3A inhibitors CYP3cide, clobetasol, and azamulin. We used three substrate probes, dibenzylfluorescein, luciferin-PPXE, and midazolam, to determine the IC

Indexed as

ClobetasolCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsAryl Hydrocarbon HydroxylasesHumansMicrosomes, LiverAryl Hydrocarbon HydroxylasesClobetasolCYP3A4 protein, humanCYP3A5 protein, humanCYP3A7 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A Inhibitors

Identifiers

PMID38702193
PMCPMC11495666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.